<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">smp</journal-id><journal-title-group><journal-title xml:lang="ru">Скорая медицинская помощь</journal-title><trans-title-group xml:lang="en"><trans-title>EMERGENCY MEDICAL CARE</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-6716</issn><publisher><publisher-name>Northwest State Medical University named after II Mechnikov</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">smp-777</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КАРДИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CARDIOLOGY</subject></subj-group></article-categories><title-group><article-title>ЗНАЧИМОСТЬ СРОКОВ БОЛЬНИЧНОЙ ВЫПИСКИ ПОСЛЕ СТЕНТИРОВАНИЯ КОРОНАРНЫХ АРТЕРИЙ НА ЧАСТОТУ РАЗВИТИЯ РЕСТЕНОЗОВ И ОБОСТРЕНИЙ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4808-1546</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абдуллаев</surname><given-names>Алигаджи Абдуллаевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий кафедрой поликлинической терапии, кардиологии и общей врачебной практики</p></bio><email xlink:type="simple">aligadzhia@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8174-3900</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хабчабов</surname><given-names>Рустам Газимагомедович</given-names></name></name-alternatives><email xlink:type="simple">rustam033@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2483-5937</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Махмудова</surname><given-names>Эльмира Рашитбековна</given-names></name></name-alternatives><email xlink:type="simple">machmydova05@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6790-1020</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гафурова</surname><given-names>Разият Магомедтагировна</given-names></name></name-alternatives><email xlink:type="simple">glad@extech.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1280-1505</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исламова</surname><given-names>Уммет Абдулхакимовна</given-names></name></name-alternatives><email xlink:type="simple">islamova-y-a@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6009-9511</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Анатова</surname><given-names>Аминат Анатовна</given-names></name></name-alternatives><email xlink:type="simple">anatovaamina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6789-8853</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Джанбулатов</surname><given-names>Мурат Абдулвагитович</given-names></name></name-alternatives><email xlink:type="simple">murat011@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>«Дагестанский государственный медицинский университет»</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>12</day><month>12</month><year>2025</year></pub-date><volume>26</volume><issue>2</issue><elocation-id>777</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Абдуллаев А.А., Хабчабов Р.Г., Махмудова Э.Р., Гафурова Р.М., Исламова У.А., Анатова А.А., Джанбулатов М.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Абдуллаев А.А., Хабчабов Р.Г., Махмудова Э.Р., Гафурова Р.М., Исламова У.А., Анатова А.А., Джанбулатов М.А.</copyright-holder><copyright-holder xml:lang="en">Абдуллаев А.А., Хабчабов Р.Г., Махмудова Э.Р., Гафурова Р.М., Исламова У.А., Анатова А.А., Джанбулатов М.А.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://smp.spb.ru/jour/article/view/777">https://smp.spb.ru/jour/article/view/777</self-uri><abstract><p>Цель исследования. Выявить значимость сроков выписки пациентов из стационара, после проведенной чрескожной коронарной ангиопластики на частоту развития рестенозов и ишемических событий. Материалы и методы. Мы проанализировали архивные истории 2021 – 2023 г., за этот период было проведено 1347 стентирований коронарных артерий, за этот же период, повторно госпитализировались 176 (13,1%) пациентов. Таким образом, в исследование вошли 176 пациентов: 111 (63,1%) мужчины и 65 (36,9%) женщин. Результаты. Исследование показало, что из 176 случаев осложнений, в группе с ранней выпиской на 1-3 сутки, их было изначально больше на 27,5%, острый инфаркт миокарда (ОИМ) наблюдался чаще на 25% (p&lt;0,05), а госпитальная смертность от ОИМ, на 33,3% (p&lt;0,05) чем у пациентов с выпиской от 4 дней и более. Заключение. Наше нерандомизированное проспективное исследование подтверждает, что ранняя выписка из стационара после стентирования, оказывает существенное влияние на развитие скорого неблагоприятного события у пациентов с ишемической болезнью сердца. Так же выявлено, что рестенозы, чаще ассоциировались с ранними сроками выписки на 1-3 сутки после стентирования – 35,2%, против 17,6% p&lt;0,05. Это привело к том, что у пациентов с ранней выпиской, острый инфаркт миокарда развивался на 25% (p&lt;0,05) чаще, а госпитальная смертность от острого инфаркта миокарда на 33,3% (p&lt;0,05), чем у пациентов с выпиской на 4 и более сутки.</p></abstract><kwd-group xml:lang="ru"><kwd>коронарное стентирование</kwd><kwd>стент</kwd><kwd>чрескожная коронарная ангиопластика</kwd><kwd>рестеноз.</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Без фин. поддержки</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Грацианский Н.А. Антитромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения // Атеротромбоз. 2019. Т. 1, №4. С. 2–17. [Gratsiansky N.A. Antiplatelet therapy for coronary heart disease. Some problems and achievements. Atherothrombosis. 2019, Vol. 1, No.4, рр. 2–17. (In Russ.)] https://doi:10.15829/1560-4071-2021-4449</mixed-citation><mixed-citation xml:lang="en">Грацианский Н.А. Антитромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения // Атеротромбоз. 2019. Т. 1, №4. С. 2–17. [Gratsiansky N.A. Antiplatelet therapy for coronary heart disease. Some problems and achievements. Atherothrombosis. 2019, Vol. 1, No.4, рр. 2–17. (In Russ.)] https://doi:10.15829/1560-4071-2021-4449</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Алекян Б.Г., Григорьян А.М., Стаферов А.В., Карапетян Н.Г. Рентгенэндоваскулярная диагностика и лечение заболеваний сердца и сосудов в Российской Федерации // Эндоваскулярная хирургия. 2018. Т. 5, №2. С. 93–240. [Alekyan B.G., Grigoryan A.M., Staferov A.V., Karapetyan N.G. X-ray endovascular diagnosis and treatment of heart and vascular diseases in the Russian Federation. Endovascular surgery. 2018. Vol. 5, No.2, рр. 93–240. (In Russ.)] https://doi.10.24183/2409-4080-2018-5-2-93240</mixed-citation><mixed-citation xml:lang="en">Алекян Б.Г., Григорьян А.М., Стаферов А.В., Карапетян Н.Г. Рентгенэндоваскулярная диагностика и лечение заболеваний сердца и сосудов в Российской Федерации // Эндоваскулярная хирургия. 2018. Т. 5, №2. С. 93–240. [Alekyan B.G., Grigoryan A.M., Staferov A.V., Karapetyan N.G. X-ray endovascular diagnosis and treatment of heart and vascular diseases in the Russian Federation. Endovascular surgery. 2018. Vol. 5, No.2, рр. 93–240. (In Russ.)] https://doi.10.24183/2409-4080-2018-5-2-93240</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Omar WA, Kumbhani DJ. The Current Literature on Bioabsorbable Stents: a Review. Curr Atheroscler Rep. 2019. 21 (12). 54–72. https://doi.org/10.1007/s11883-019-0816-4.</mixed-citation><mixed-citation xml:lang="en">Omar WA, Kumbhani DJ. The Current Literature on Bioabsorbable Stents: a Review. Curr    Atheroscler Rep. 2019. 21 (12). 54–72. https://doi.org/10.1007/s11883-019-0816-4.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Giacchi G, Ortega-Paz L, Brugaletta S, Ishida K, Sabaté M. Bioresorbable vascular scaffolds technology: current use and future developments. Med Devices (Auckl). 2019. 9 (5). 185–198. https://doi.org/10.2147/MDER.S90461</mixed-citation><mixed-citation xml:lang="en">Giacchi G, Ortega-Paz L, Brugaletta S, Ishida K, Sabaté M. Bioresorbable vascular scaffolds technology: current use and future developments. Med Devices (Auckl). 2019. 9 (5). 185–198. https://doi.org/10.2147/MDER.S90461</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Verdoia M, Kedhi E, Suryapranata H, Galasso G, Dudek D, De Luca G. Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials. Catheter Cardiovasc Interv. 2020. 96 (4). 813–824. https://doi.org/10.1002/ccd.28594</mixed-citation><mixed-citation xml:lang="en">Verdoia M, Kedhi E, Suryapranata H, Galasso G, Dudek D, De Luca G. Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials. Catheter Cardiovasc Interv. 2020. 96 (4). 813–824. https://doi.org/10.1002/ccd.28594</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Иоселиани Д.Г., Асадов Д.А., Фоменко В.В., Азаров А.В., Семитко С.П. Пятилетний результат имплантации биодеградируемых стентов Absorb по методике бифуркационного стентирования // Кардиоваскулярная терапия и профилактика. – 2021. Т. 20, №4, С. 28–64. [Ioseliani D.G., Asadov D.A., Fomenko V.V., Azarov A.V., Semitko S.P. Five-year result of implantation of bioabsorbable stents Absorb using the bifurcation stenting technique. Cardiovascular Therapy and Prevention. 2021. 20, (4), рр. 28–64. (In Russ.) ] https://doi.org/10.15829/1728-8800-2021-2864</mixed-citation><mixed-citation xml:lang="en">Иоселиани Д.Г., Асадов Д.А., Фоменко В.В., Азаров А.В., Семитко С.П. Пятилетний результат имплантации биодеградируемых стентов Absorb по методике бифуркационного стентирования // Кардиоваскулярная терапия и профилактика. – 2021. Т. 20, №4, С. 28–64. [Ioseliani D.G., Asadov D.A., Fomenko V.V., Azarov A.V., Semitko S.P. Five-year result of implantation of bioabsorbable stents Absorb using the bifurcation stenting technique. Cardiovascular Therapy and Prevention. 2021. 20, (4), рр. 28–64. (In Russ.) ] https://doi.org/10.15829/1728-8800-2021-2864</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chun Shing Kwok, Malcolm Bell, H. Vernon Anderson, Discharge Against Medical Advice After Percutaneous Coronary Intervention in the United States. J Am Coll Cardiol Intv. 2018. 11 (14). 1354–64. https://doi: 10.1016/j.jcin.2018.03.049</mixed-citation><mixed-citation xml:lang="en">Chun Shing Kwok, Malcolm Bell, H. Vernon Anderson, Discharge Against Medical Advice After Percutaneous Coronary Intervention in the United States. J Am Coll Cardiol Intv. 2018. 11 (14). 1354–64. https://doi: 10.1016/j.jcin.2018.03.049</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Smits PC, Chang CC, Chevalier B, West NEJ, Gori T, Barbato E. Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomized clinical trial. EuroIntervention. 2020. 16 (8). 645–653. https://doi.org/10.4244/EIJ-D-19-01079</mixed-citation><mixed-citation xml:lang="en">Smits PC, Chang CC, Chevalier B, West NEJ, Gori T, Barbato E. Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomized clinical trial. EuroIntervention. 2020. 16 (8). 645–653. https://doi.org/10.4244/EIJ-D-19-01079</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kraak RP, Tijssen RYG, van Dongen IM, Elias J, Hofma SH, van der Schaaf RJ. Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial. EuroIntervention. 2020. 16 (11). 904–912. https://doi.org/10.4244/EIJ-D-18-00884</mixed-citation><mixed-citation xml:lang="en">Kraak RP, Tijssen RYG, van Dongen IM, Elias J, Hofma SH, van der Schaaf RJ. Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial. EuroIntervention. 2020. 16 (11). 904–912. https://doi.org/10.4244/EIJ-D-18-00884</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ortega-Paz L, Brugaletta S, Sabaté M. Impact of PSP Technique on Clinical Outcomes Following Bioresorbable Scaffolds Implantation. J Clin Med. 2018. 7 (2). 27-39. https://doi.org/10.3390/jcm7020027</mixed-citation><mixed-citation xml:lang="en">Ortega-Paz L, Brugaletta S, Sabaté M. Impact of PSP Technique on Clinical Outcomes Following Bioresorbable Scaffolds Implantation. J Clin Med. 2018. 7 (2). 27-39. https://doi.org/10.3390/jcm7020027</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Keh YS, Yap J, Yeo KK, Koh TH, Eeckhout E. Clinical Outcomes of Bioresorbable Scaffold in Coronary Artery Disease: A Systematic Literature Review. J Interv Cardiol. 2018. 29 (1). 57–69. https://doi.org/10.1111/joic.12260</mixed-citation><mixed-citation xml:lang="en">Keh YS, Yap J, Yeo KK, Koh TH, Eeckhout E. Clinical Outcomes of Bioresorbable Scaffold in Coronary Artery Disease: A Systematic Literature Review. J Interv Cardiol. 2018. 29 (1). 57–69. https://doi.org/10.1111/joic.12260</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar A, Gogas BD, Thompson EW, Burnett GM, Molony D, Hosseini H. Bioresorbable vascular scaffolds versus everolimus-eluting stents: a biomechanical analysis of the ABSORB III Imaging substudy. EuroIntervention. 2020. 16 (12). 989–996. https://doi.org/10.4244/EIJ-D-19-01128</mixed-citation><mixed-citation xml:lang="en">Kumar A, Gogas BD, Thompson EW, Burnett GM, Molony D, Hosseini H. Bioresorbable vascular scaffolds versus everolimus-eluting stents: a biomechanical analysis of the ABSORB III Imaging substudy. EuroIntervention. 2020. 16 (12). 989–996. https://doi.org/10.4244/EIJ-D-19-01128</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Danzi GB, Bernelli C, Cerrato E. Outcomes of Optimised Implantation Technique with Bioresorbable scaffolds: A Pooled Analysis of ABSORB-IV and COMPARE-ABSORB Trials. Cardiovasc Revasc Med. 2020. 21 (4). 559–561. https://doi.org/10.1016/j.carrev.2019.07.018</mixed-citation><mixed-citation xml:lang="en">Danzi GB, Bernelli C, Cerrato E. Outcomes of Optimised Implantation Technique with Bioresorbable scaffolds: A Pooled Analysis of ABSORB-IV and COMPARE-ABSORB Trials. Cardiovasc Revasc Med. 2020. 21 (4). 559–561. https://doi.org/10.1016/j.carrev.2019.07.018</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Badour SA, Dimitrova KR, Kanei Y, Tranbaugh RF, Hajjar MM, Kabour A et al. First and second generation DESs reduce diabetes adverse effect on mortality and re-intervention in multivessel coronary disease: 9-Year analysis. Cardiovascular Revascularization Medicine. 2017. 18 (4). 265–73. https://doi.org/10.1016/j.carrev.2017.01.012</mixed-citation><mixed-citation xml:lang="en">Badour SA, Dimitrova KR, Kanei Y, Tranbaugh RF, Hajjar MM, Kabour A et al. First and second generation DESs reduce diabetes adverse effect on mortality and re-intervention in multivessel coronary disease: 9-Year analysis. Cardiovascular Revascularization Medicine. 2017. 18 (4). 265–73. https://doi.org/10.1016/j.carrev.2017.01.012</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mangione FM, Biering-Sørensen T, Nochioka K, Jatene T, Silvestre OM, Hansen KW et al. Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials. Catheterization and Cardiovascular Interventions. 2018. 91 (5). 867–73. https://doi.org/10.1002/ccd.27200</mixed-citation><mixed-citation xml:lang="en">Mangione FM, Biering-Sørensen T, Nochioka K, Jatene T, Silvestre OM, Hansen KW et al. Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials. Catheterization and Cardiovascular Interventions. 2018. 91 (5). 867–73. https://doi.org/10.1002/ccd.27200</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zandvoort LJC, Bommel RJ, Masdjedi K, Tovar Forero MN, Lemmert MM, Wilschut J et al. Long‐term outcome in patients treated with first‐ versus second‐generation drug‐eluting stents for the treatment of unprotected left main coronary artery stenosis. Catheterization and Cardiovascular Interventions. 2019. 2 (8). 38–47. https://doi.org/10.1002/ccd.28387</mixed-citation><mixed-citation xml:lang="en">Zandvoort LJC, Bommel RJ, Masdjedi K, Tovar Forero MN, Lemmert MM, Wilschut J et al. Long‐term outcome in patients treated with first‐ versus second‐generation drug‐eluting stents for the treatment of unprotected left main coronary artery stenosis. Catheterization and Cardiovascular Interventions. 2019. 2 (8). 38–47. https://doi.org/10.1002/ccd.28387</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
